Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Abstract Background Non-dystrophic myotonias (NDMs) comprise muscle chloride and sodium channelopathies due to genetic defects of the CLCN1- and SCN4A-channels. No licensed antimyotonic treatment has been available until approval of mexiletine (NaMuscla®) for adult patients by the EMA in December 20...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ann-Marie Chapman, Marieke Schurer, Laure Weijers, Amer Omar, Hiba Lee, Alla Zozulya Weidenfeller, Crispin Ellis, Shaneil Sonecha, Christiane Schneider-Gold
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Non-dystrophic myotonia
Delphi panel
Mexiletine (NaMuscla)
Quality of life
Healthcare resource utilisation
INQoL
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/2cdb57b2b6a248bc977784e77cd32aaa
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares